<https://rdf.molmedb.upol.cz/reference/ref3256> <http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane46>,
		<https://identifiers.org/molmedb/MM490071>;
	<http://purl.org/ontology/bibo/pmid> "28284804"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/ontology/bibo/doi> "10.1016/j.bmcl.2016.10.085"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method71>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/bibliographicCitation> "Xu J, Lin S, Myers RW, Addona G, Berger JP, Campbell B, Chen HS, Chen Z, Eiermann GJ, Elowe NH, Farrer BT, Feng W, Fu Q, Kats-Kagan R, Kavana M, Malkani S, McMasters DR, Mitra K, Pachanski MJ, Tong X, Trujillo ME, Xu L, Zhang B, Zhang F, Zhang R, Parmee ER.: Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus. Bioorg Med Chem Lett, Volume 27 (9), 2017"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/interaction/int1009565> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3256> .
